Kornimate/medical-research-clean huggingface dataset:
high-dose vitamin d3 supplementation in the treatment of human immune deficiency virus patients trial

Conditions: HIV-1-infection; Hypovitaminosis D

Summary: high-dose vitamin d3 in the treatment of human immune deficiency virus patients, a double-blind randomized control trial human immunodeficiency virus is a key challenge for global health. vitamin d deficiency is common in people living with hiv infection. antiretroviral therapy may create unique risk factors for vitamin d insufficiency, including alterations of vitamin d metabolism by art.

the study is designed to evaluate the effect of high dose vitamin-d supplementation in the treatment of hiv patients with antiretroviral therapy. furthermore, in secondary outcomes study will evaluate the effects of high dose vitamin-d supplementation by pre \& post assessments of cd4 count and pcr count. secondary outcomes also includes the effects of high dose vitamin-d supplementation by pre \& post assessments of sgpt, sgot, alp and bilirubin. tertiary outcomes includes the effects of high dose vitamin-d supplementation by pre \& post assessments of hb, lymphocytes, monocytes, eosinophil, platelet count and basophil count. a sample size of 95 patients were recruited in said mitha teaching hospital lahore. study is planned in two groups including 1) arv + vitamin-d3 2) arv + placebo. methods/design: a randomized placebo controlled double-blind clinical trial of patients with age 19-50 years. the primary outcome will be assessed by analyzing the difference change in the vitamin-d levels from day 1 to week 12. secondary outcomes including viral load count, cd4 count, elevated levels of lfts, will also be assessed by analyzing the mean difference in their values on week 12 after the supplementation of high dose vitamin-d. tertiary outcomes (hematology) including hb, hct, tlc, eosinophil's count, neutrophils count, monocytes and platelets data will be collected on a predefined performa. all information will be entered in spss for the analysis. discussion: high dose vitamin d supplementation in hiv-infected patients has not been previously investigated in pakistan and it is unknown whether increasing levels is associated with improved clinical outcome or not. therefore, it is significant to conduct a study to know the effect of vitamin d in the treatment of hiv patients with antiretroviral therapy. keywords: aids, hiv, anti-retroviral therapy, high dose 25-hydroxy vitamin-d level, cd4 count, viral load.

Eligibility criteria:
inclusion criteria: 1. age from 19 years and above 2. vitamin-d levels less than 20ng/ml 3. not taking any kind of vitamin-d supplementation or mega doses for last six months 4. written informed consent form 5. pcr positive patients exclusion criteria: 1. pregnant and lactating women 2. ability to take study medication orally
efficacy study of ecabet ophthalmic solution in dry eye disease

Conditions: Dry Eye Disease

Summary: efficacy study of ecabet ophthalmic solution in dry eye disease


Eligibility criteria:
inclusion criteria: * diagnosed with dry eye disease exclusion criteria: * dry eye disease secondary to surgery
rural colon cancer screening toolkit intervention

Conditions: Colon Cancer Screening

Summary: less than half of all positive fecal immunochemical testing (fit)s are followed-up by colonoscopy, thus limiting the full potential of colorectal cancer (crc) screening to reduce mortality. given the need for coordination in order to achieve high rates of follow-up, multilevel approaches are needed. such approaches could be particularly beneficial in communities and populations that experience cancer disparities and have fewer specialty providers, but most data focuses on large systems or urban areas. the academic-community health system collaboration is uniquely poised to address this research and service gap. the persistent poverty and health disparities in rural southern illinois set the stage for truly impactful research. the investigators' approach will serve as a model for multilevel interventions in rural settings, inform future work addressing other health disparities, and fill a gap in rigorous trials of crc screening follow-up in rural areas.


Eligibility criteria:
inclusion criteria for primary care clinic sites * physician hospital organization (pho) affiliated with southern illinois healthcare exclusion criteria for primary care clinic sites * not a part of the pho inclusion criteria for physicians and staff at primary care clinic sites * employment at the relevant clinic at the time of the study exclusion criteria for physicians and staff at primary care clinic sites * not employed at the relevant clinic at the time of the study inclusion criteria for patients * age 45-75 during the study period * must be patient of the selected primary care clinic sites exclusion criteria for patients * younger than 45 years of age or older than 75 years of age during the study period * not a patient of the selected primary care clinic sites inclusion criteria for community members * age 45-75 at the time of the health fair or screening event * able to undergo stool testing as determined by sih staff at the health fair or screening event exclusion criteria for community members * younger than 45 years of age or older than 75 years of age * unable to undergo stool testing
bathing bundle regimen in reducing gynecological surgical site infection in patients undergoing surgery

Conditions: Malignant Female Reproductive System Neoplasm

Summary: this pilot clinical trial studies bathing bundle regimen in reducing gynecological surgical site infection in patients undergoing surgery. a bathing bundle regimen may reduce the risk of wound infection, extended length of hospital stay, readmission into the hospital, and the overall healthcare costs in patients undergoing surgery.

primary objectives: i. to investigate whether gynecology surgical patients using a bathing bundle using chlorhexidine gluconate (chg) 4% skin prep solution (intervention group a) have a lower incidence of surgical site infection (ssi) than patients treated with the current standard of care (patient's choice of antibacterial soap). standard of care results will be based on historical information gathered on roswell park cancer institute (rpci) gynecology (gyn) patients prior to july 1, 2010 (historical control group b). outline: patients undergo preoperative preparation with the "bathing bundle" comprising chg 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery. after completion of study treatment, patients are followed up for 2 years.

Eligibility criteria:
inclusion criteria: * gyn surgical patients scheduled for abdominal surgery exclusion criteria: * patients with known hypersensitivity to chlorhexidine * gyn non-surgical patients or surgical patients that will not have an abdominal incision (i.e. vaginal procedures)
a study of an experimental nasal spray in subjects with early signs of the common cold

Conditions: Common Cold

Summary: this study will test 200 people to see if an experimental nasal spray has an effect on symptoms of the common cold if used when the symptoms start. at the first visit to the clinic, potential subjects will have tests to make sure they qualify to participate in the study. if they qualify, they will have an equal chance of receiving the experimental nasal spray or a sham nasal spray (one that does not have the experimental formula). at the first visit, subjects will receive their assigned nasal spray and use it once at the clinic. they will also receive a booklet called a diary. subjects will take the rest of their treatments for day 1 at home, and for the next six days, they will use the nasal spray four times per day and record their symptoms in the diary, as instructed. then subjects will come back to the clinic for a final visit.

this is an investigation in healthy subjects with early signs of common cold. subjects will be randomly assigned in a 1:1 ratio to receive either polymeric nasal spray or a matching placebo nasal spray. subjects will be screened for eligibility and randomized to treatment at the screening/ randomization visit (day 1). subjects will apply the first dose of the nasal spray at this visit under supervision. the other applications will take place at home on day 1. on days 2 through 7, subjects will use their assigned nasal spray as 2 sprays per nostril, 4 times per day. one follow up visit will be conducted within 3 days of the last application of nasal spray. enrollment will continue until 200 subjects have completed the investigation (100 per treatment group). the subject and the investigative staff will be blinded to the assigned nasal spray. efficacy will be measured, and recorded in the subject's diary, and safety will be assessed by reported aes and ades.

Eligibility criteria:
inclusion criteria: * have early signs of a common cold: if female of child-bearing potential, have a negative pregnancy test at screening. * have signed and dated the informed consent document, indicating that they have been informed of all pertinent aspects of the investigation * are willing and able to comply with scheduled visits, treatment plan, and other investigation procedures exclusion criteria: * have had common cold or flu-like symptoms outside the protocol-specified parameters. * are current smokers as defined by the protocol. * have any medical history or condition or use any drug or device that (per protocol or in the opinion of the investigator) might compromise subject safety, participation in the trial, action of the investigational device, or results of the investigation.. * are related to anyone involved with the conduct of the investigation.
the femscope calm collect device

Conditions: Cervical Cancer

Summary: the goal of this clinical trial is to determine if cervical cells collected by the femscope calm collect device in women (sex assigned at birth) of adult age are the same quality and quantity as the cervical cells collected by the traditional brush method for cervical cancer screening. the main questions it aims to answer are: 1. increase the number of women who get screened for cervical cancer. 2. improve patient acceptance of getting cervical screening on a routine basis. 3. decrease pain and discomfort for patients having a pap smear procedure. participants will * have two vaginal exams to collect cervical cells. * state decreased pain and discomfort for patients having a pap smear procedure. * the femscope calm collect device (fccd) will be more comfortable for the patient as measured by a patient satisfaction survey comparing the fccd and the traditional speculum method of obtaining cervical cells.

the femscope calm collect device is a novel medical device intended for vaginal inspection, cervical cancer screening, rectal cancer screening, and discharge/cell retrieval. the device allows for increased comfort (emotionally and physically) to the patient while meeting the requirements of a genital exam. the femscope system includes a light and camera, enabling visualization of the vagina and cervix and display on a screen. it also provides brushing/retrieval means, allowing the provider to obtain necessary cervical cells for a pap smear, hpv, and specimens needed for sexually transmitted disease (sti) testing. the system will also allow the direct visualization of rectal tissue sampled for human papillomavirus/rectal cancer. the system is designed to replace the speculum, provide the tools needed to perform comprehensive pelvic and topical rectal exams, provide cervical cancer screens, and be cost-competitive with existing speculum and tissue swab systems. it is simple and easy to use. the device comprises a reusable base portion, a removable protective sleeve, and a single-use cell retrieval cap for improved cost-effectiveness. this instrument will revolutionize women's health care, replacing the antiquated speculum examination with modern scopes like those used to visualize many other portions of the human body. having the instrument designed to facilitate exams in the lgbtqia community is sorely needed and will improve gynecologic and genital examinations in that community

Eligibility criteria:
inclusion criteria: - healthy female ages 21-45 with female reproductive organs present at the time of study. exclusion criteria: * pregnancy * menopausal * age less than 21 years * age of 46+ years * history of reproductive cancer * hysterectomy

Keywords: cervical cancer screening
silver diamine fluoride for caries prevention in removable partial dentures wearers

Conditions: Dental Caries; Dental Caries of Root Surface

Summary: this study measures and compares the effect of silver diamine fluoride (sdf) on caries increment in removable partial denture wearers. half of the participants will sdf and while the other half will receive placebo.

removable partial dentures are commonly constructed to replace missing teeth. it is observed that removable partial denture wearers are susceptible to dental caries. the mode of action of silver diamine fluoride on caries prevention is dual: fluoride ions interact synergistically with silver to react with hydroxyapatite to form fluorapatite, and silver is bactericidal by reacting with the thiol groups of the amino and nucleic acids that halt the metabolic and reproductive functions of the cariogenic bacteria.

Eligibility criteria:
inclusion criteria: * patients who are wearing removable partial dentures constructed by staff or students at the prince philip dental hospital are recruited exclusion criteria: * if they have less than 4 teeth in any dental arch, have advanced periodontal disease in 2 or more sextants, have received therapeutic radiation of the head and neck region, have concurrent systemic illness that alters salivary flow, or have participated in a clinical trial within 6 months before the commencement of participation in this study.

Keywords: removable partial denture silver diamine fluoride
study to investigate the management of hypertension and efficacy of azd2171 in patients with advanced solid tumours

Conditions: Tumors

Summary: the purpose of this study is to determine whether doses of 30 mg and 45 mg azd2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of advanced solid tumour, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitor. exclusion criteria: * prior treatment with a vegf inhibitor * poorly controlled hypertension

Keywords: advanced solid tumours phase ii hypertension recentin
effect of azithromycin in preventing premature labour

Conditions: Pregnant With Complication

Summary: this is a prospective observational case controlled study. the control group will include pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy. the test group will involve pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin

a prospective randomized clinical study was conducted in the outpatient clinic of the gynecology department of beni suef university hospital, beni-suef, egypt, between october 01, 2021, and april 30, 2022. the study included 211 pregnant women aged between 20 to 41 years. these patients were randomized into three groups. the first group which was the control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy. while the second group which was the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month. . the third group was the second test group in which the pregnant women administerated azithromycin and clindamycin (dalacin®) vaginal gel 5 times per month.

Eligibility criteria:
inclusion criteria: * pregnant women with \<34 weeks of gestation, * hospitalization for risk of preterm labour, * threat of preterm labour, or preterm labour itself. * threat of preterm labour and preterm labour will have to be diagnosis cited in the medical record by the physician. * women at risk of preterm labour must have one of the following conditions cited in their record: sludge, short cervix, cerclage, or bulging membranes exclusion criteria: * patients were excluded from the current study in case of the use of antibiotics within 14 days before the admission (except for pericerclage prophylaxis, or streptococcus b prophylaxis), pprom or fetal extraction required \<37 weeks.
proactive population health management of cardiovascular disease in primary care using the prospera-program.

Conditions: Cardiovascular Diseases

Summary: the prospera-program is a complex multilevel approach that includes training for healthcare providers, a risk assessment process, and decision support tools to help match patients with the appropriate treatment based on their care needs. the goal of this clinical trial is to determine if the prospera-program can improve the cardiovascular risk profile in patients aged 40-90 years enrolled in primary care programs for increased cardiovascular risk, such as cardiovascular disease, increased vascular risk, or diabetes. the main question it aims to answer is: • does the cardiovascular risk profile improve for patients using the prospera-program? researchers will compare the prospera-program with standard cardiovascular care to see if the program enhances cardiovascular population health in primary care. additionally, the study will assess how well the prospera-program fits into the workflow of primary care providers and supports shared decision-making. participants will: * receive a consultation with their general practitioner or practice nurse according to the prospera-program. * have their routinely collected healthcare data used for evaluation. * be asked to complete a questionnaire or participate in an interview (for a subset of patients).


Eligibility criteria:
inclusion criteria: * age \> 40 years and ≤ 90 years * patient in a primary care practice enrolled in this study * included in the cardiovascular disease (cvd), increased vascular risk (ivr) or diabetes mellitus (dm) dutch integrated care programs * additional criteria for subgroup that receives questionnaires: able to communicate in the dutch and/or english language exclusion criteria: * patients with diabetes mellitus type i * patients receiving palliative care * patients with any form of cognitive impairment diseases such as dementia or alzheimer * patients who are treated in other integrated care programs because of their frailty (e.g. elderly who are treated in the 'kwetsbare ouderen chronische zorgprogramma')

Keywords: primary care population health management implementation
development and validation of a prediction model for depression and anxiety in perioperative elderly adults

Conditions: Predictive Model

Summary: anxiety and depression in later life are highly prevalent, often appear as comorbid disorders, and have many adverse consequences for both the individual and society. given the disease burden, the large influx of new cases, and the economic costs, efforts should be made to prevent the onset of anxiety and depression in later life. preventive interventions are likely to become more cost effective when they are targeted at elderly who have been exposed to risk factors known to be predictive of the onset of anxiety and/or depression. as the population aging is speeding up, senile diseases have become a significant and severe public health problem, influencing national health. more than 20 million elderly patients undergo surgery each year in china, accounting for a quarter of the population who undergo surgery. therefore, it is necessary to construct a predictive model of anxiety and depression in perioperative elderly hospitalized patients

more than 20 million elderly patients undergo surgery each year in china, accounting for a quarter of the population who undergo surgery. therefore, it is necessary to construct a predictive model of anxiety and depression in perioperative elderly hospitalized patients. in 2015, the who introduced the concept of "healthy ageing" for global ageing, with a focus on the mental health of older people at its core. previous studies have found a 31 percent risk of anxiety and 29 percent risk of depression in older perioperative patients. therefore, optimizing perioperative mental health management in older patients remains one of the challenges facing clinicians.

Eligibility criteria:
inclusion criteria: 1. elective non-cardiac surgery, 2. american society of aneshesiologists (asa) classification ⅰ \~ ⅲ, 3. patients over age 65. exclusion criteria: 1. patient refused follow-up study, 2. missing data exceeding 20%, 3. went to icu or died after surgery, 4. have a history of any mental disorders such as epilepsy, parkinson's disease, depression, anxiety, sleep disorders, or are currently taking relevant intervention drugs 5) patients with severe deafness, dementia or speech impairment.

Keywords: predicted model depression anxiety elderly patient
evaluation of aging, autonomic nervous system activity and cardiovascular events

Conditions: Healthy

Summary: the regulatory effects of the autonomic nervous system (ans) concern almost all organs which permanently feed information back to this global biological vigilance system controlling allostasis. heart rate fluctuations are highly dependent on ans control, making the heart one of the best indicators of ans activity. low ans activity level is associated with severe cardiac and cerebral events, as well as to death from any cause in the general population. this proof study was hence designed to evaluate ans activity levels among a healthy retired population, but should these levels decline overtime, to use this as a predictor of cardiovascular and cerebrovascular events, taking into account established cardiovascular risk factors.

the main goal of this proof study is to evaluate, on a selected prospective cohort of subjects aged 65 years upon study entry, the prognostic values of ans activity levels measured at preset times, and more specifically, of its decline over the follow-up period, for fatal and non-fatal cardiovascular and cerebrovascular events.

Eligibility criteria:
inclusion criteria: * 65 years old * informed consent signed exclusion criteria: * prior myocardiac infarction * prior stroke * hearth failure * atrial fibrillation * insulin-treated diabetes mellitus * cardiac pacemaker * disease limiting life expectancy to \< 5 years * contraindication to brain mri * living in an institution

Keywords: aging cardiovascular risk factors autonomic nervous system stroke myocardiac infarction neuropsychological evaluation prospective cohort